Clinical Trial: Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals with Severe Mental Illness

This study is currently recruiting patients.

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)

Purpose

The purpose of this study is to develop a cognitive behavioral therapy (CBT) program for treating symptoms of post-traumatic stress disorder (PTSD) in people with severe mental illnesses (SMI) who are treated within community mental health systems.

Condition Treatment or Intervention Phase
Stress Disorders, Post-Traumatic
Schizophrenia
Psychotic Disorders
 Behavior: Cognitive Behavioral Therapy (CBT)
Phase II

MedlinePlus related topics:  Mental Health;   Post-Traumatic Stress Disorder;   Schizophrenia

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title: CBT for PTSD and SMI in Community Mental Health Centers

Further Study Details: 

Expected Total Enrollment:  60

Study start: January 2004;  Expected completion: December 2005

A significant proportion of people with SMI who are treated within the public sector also suffer from PTSD. Evidence suggests that these individuals often receive inadequate mental health services because effective treatments have not been explored. This study will develop and implement a CBT treatment that is designed specifically for the SMI/PTSD population.

In the first year of the study, a treatment manual and a CBT treatment model, including education, social skills training, and exposure therapy, will be developed. In the following two years, the treatment program will be tested in individuals with SMI and PTSD. Scale ratings, self-report checklists, and daily logs of behavior will be used to assess PTSD symptoms. Scale ratings and self-report surveys will also be used to measure hostility, functional status, depression and schizophrenia symptoms, and satisfaction with the study. Assessments will be made throughout the study.

Eligibility

Ages Eligible for Study:  18 Years   -   80 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • Diagnosis of PTSD and schizophrenia or schizoaffective disorder
  • Active involvement in case management

Exclusion Criteria:

  • Suicide risk

Location and Contact Information


Massachusetts
      Boston University School of Medicine, Boston,  Massachusetts,  02118,  United States; Recruiting
Todd Buckley, PhD  617-278-4501    Todd.Buckley@med.va.gov 

South Carolina
      Medical University of South Carolina, Charleston,  South Carolina,  29401,  United States; Recruiting
Chris Frueh, PhD  843-789-7967    fruehbc@musc.edu 
Chris Frueh, PhD,  Principal Investigator

      South Carolina Department of Mental Health, Columbia,  South Carolina,  29202,  United States; Recruiting
Karen Cusack, PhD  843-727-2000    cusackkj@musc.edu 

More Information

Study ID Numbers:  MH65248-01A1
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  March 5, 2004
ClinicalTrials.gov Identifier:  NCT00078741
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources